Search

Psoriasis is a polygenic, systemic inflammatory disease seen in 2% to 3% of the population and leads to a serious deterioration in the quality of life. As a result, studies on the pathophysiology of this disease have led to the development of cytokine-targeted therapies, especially the widespread use of treatments targeting tumor necrosis factor-alpha (TNF-α). The role of TNF-α in inflammation and important physiological pathways has increased safety concerns. In the literature, it has been reported that infections, cardiac failure, neurological diseases, and malignancies may develop related to the use of anti-TNF-α agents. In this case report, a 59-year-old male patient was started on adalimumab as a biological agent for erythrodermic psoriasis. Twenty-four months after starting biological agent therapy, hard nodules occurred under his skin in both the inguinal and axillary regions. The patient was diagnosed with diffuse large B-cell lymphoma based on his histopathological and laboratory examinations. This case report aims to discuss the specific malignancies that may develop from anti-TNF-α agents and the potential pathophysiological mechanisms suggested in the current literature. [ABSTRACT FROM AUTHOR]

Keywords: COVID-19; cutaneous vasculitis; inclusion bodies; skin manifestation EN COVID-19 cutaneous vasculitis inclusion bodies skin manifestation 27 29 3 12/29/21 20220101 NES 220101 ACKNOWLEDGEMENTS The patient presented in this manuscript gave written informed consent to the publication. Leukocytoclastic vasculitis secondary to COVID-19 infection presenting with inclusion bodies: A histopathological correlation Various skin manifestations, such as petechiae, livedoid patch, and pseudo-chilblains, associated with vasculopathy have been reported.1-3 Herein, we present a case of leukocytoclastic vasculitis (LCV) in a patient diagnosed with COVID-19 infection. [Extracted from the article]

Copyright of Dermatoz is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

In a recent population-based study, the 21-year cumulative risk of getting a subsequent SCC after a first melanoma was 4.6% for males and 2.6% for females.3 Our patient developed pBD 4 years after the initial melanoma diagnosis. Although the dermoscopic features of the lesion were not pointing clearly toward either melanoma or pBD, the previous melanoma diagnosis of the patient drew our attention. Pigmented Bowen's disease with atypical dermoscopic findings mimicking malignant melanoma in a patient of melanoma: A case report. [Extracted from the article]